Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Accumulated Depreciation (2020 - 2024)

Historic Accumulated Depreciation for TScan Therapeutics (TCRX) over the last 5 years, with Q4 2024 value amounting to $18.7 million.

  • TScan Therapeutics' Accumulated Depreciation rose 2813.59% to $18.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.7 million, marking a year-over-year increase of 2813.59%. This contributed to the annual value of $18.7 million for FY2024, which is 2813.59% up from last year.
  • Per TScan Therapeutics' latest filing, its Accumulated Depreciation stood at $18.7 million for Q4 2024, which was up 2813.59% from $14.6 million recorded in Q4 2023.
  • TScan Therapeutics' 5-year Accumulated Depreciation high stood at $18.7 million for Q4 2024, and its period low was $1.8 million during Q4 2020.
  • For the 5-year period, TScan Therapeutics' Accumulated Depreciation averaged around $10.1 million, with its median value being $10.2 million (2022).
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first skyrocketed by 18962.96% in 2021, then soared by 2813.59% in 2024.
  • TScan Therapeutics' Accumulated Depreciation (Quarter) stood at $1.8 million in 2020, then skyrocketed by 189.63% to $5.1 million in 2021, then skyrocketed by 101.06% to $10.2 million in 2022, then soared by 42.83% to $14.6 million in 2023, then rose by 28.14% to $18.7 million in 2024.
  • Its last three reported values are $18.7 million in Q4 2024, $14.6 million for Q4 2023, and $10.2 million during Q4 2022.